Biological products include a wide range of products such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Many biologics are produced using recombinant DNA technology. Biologics are the best used drugs for genetic disorders. New technologies, novel therapies are emerging for the manufacturing of new biologics which holds a prominent future for biologics market. Biologics are widely used to prevent, treat, diagnose, or cure a variety of diseases including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases. Biologics are also used in treatment of rare diseases in children like for treatment of Batten disease, cerliponase alfa was approved in 2017 for the first time by U.S. Food and Drug Administration (FDA).
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-sample/2663
Global Biologics Market, by Drug Class (Monoclonal Antibody, Vaccine, Recombinant Insulin, Human Growth Hormone, Blood Factor, Fusion Protein, Erythropoietin, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Cell Therapy, Gene Therapy, Oligonucleotides and Others (Peptide, Botulinum Toxin, and Others)), By Therapeutic Application (Oncology, Metabolic Disorders, Autoimmune/Immunologic Diseases, Ophthalmic Diseases, Inflammatory Bowel Diseases (IBDs), Respiratory Disorders, Neurological Disorders, Musculoskeletal Disorders (MSDs), Cardiovascular Diseases (CVDs), Infectious Diseases, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 255.19 billion in 2019 and is expected to exhibit a CAGR of 7.6% over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.
Key players in the market are involved in strategic collaborations with leading biopharmaceutical companies and research institutes for development of novel biopharmaceutical and biomedicines. Such strategic collaborations are expected to create conducive environment for growth of the global biologics market over the forecast period. For instance, in 2015, the University of Liverpool entered into a strategic collaboration with Medicines Patent Pool (MPP). Under the collaboration agreement, the University of Liverpool will license its patented Solid Drug Nanoparticle (SDN) technology, which can improve delivery of current HIV therapies into the body, to MPP.
Get Discount For First Time Buyers
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2663
Furthermore, in 2016, Biocon Ltd., a wholly owned subsidiary of Biocon SA entered into a collaboration with Laboratories PiSA S.A. de C.V, a Mexico-based company for co-development and commercialization of generic recombinant human insulin (rh-insulin) in the U.S. market
In 2017, AbCellera Biologics, Inc. entered into a collaboration with GlaxoSmithKline plc. for discovery of monoclonal antibodies against an undisclosed membrane protein target.
Key Takeaways of the Global Biologics Market:
- The global biologics market is expected to exhibit a CAGR of 7.6% over the forecast period (2019-2027), owing to increasing strategic collaborations by key players for biopharmaceutical and biomedicine drugs
- Among drug class, monoclonal antibodies segment is expected to account for a major revenue share by 2027, owing to increasing regulatory approvals and launches of novel monoclonal antibodies for various indications. For instance, in February 2018, Novartis received the U.S Food and Drug Administration (FDA) approval for label update of its Cosentyx (secukinumab), the first interleukin-17A (IL-17A) inhibitor to treat moderate-to-severe plaque psoriasis.
- Major players operating in the global biologics market include Bristol-Myers Squibb Company (BMS), Merck & Co., Inc., Roche AG, Merck KGaA, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc, Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen S.A., and Allergan Plc.
Browse 35 Market Data Tables and 49 Figures spread through 329 Pages and in-depth TOC on “Global Biologics Market, by Drug Class (Monoclonal Antibody, Vaccine, Recombinant Insulin, Human Growth Hormone, Blood Factor, Fusion Protein, Erythropoietin, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Cell Therapy, Gene Therapy, Oligonucleotides and Others (Peptide, Botulinum Toxin, and Others)), By Therapeutic Application (Oncology, Metabolic Disorders, Autoimmune/Immunologic Diseases, Ophthalmic Diseases, Inflammatory Bowel Diseases (IBDs), Respiratory Disorders, Neurological Disorders, Musculoskeletal Disorders (MSDs), Cardiovascular Diseases (CVDs), Infectious Diseases, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2027”
To know the latest trends and insights related to global biologics market press release, click the link below: https://www.coherentmarketinsights.com/press-release/biologics-market-3010
Global Biologics Market: Taxonomy
The global biologics market is segmented on the basis of product type, application, end user, and region.
By Product Type
- Monoclonal Antibodies
- Recombinant Hormones/Proteins
- Cell Therapy
- Gene Therapy
- Infectious Diseases
- Autoimmune Diseases
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027